MDT

84.06

+0.04%↑

VEEV

226.15

-0.01%↓

A

105.7

-0.57%↓

WBA

11

+0.09%↑

CHE

551.68

-1.39%↓

MDT

84.06

+0.04%↑

VEEV

226.15

-0.01%↓

A

105.7

-0.57%↓

WBA

11

+0.09%↑

CHE

551.68

-1.39%↓

MDT

84.06

+0.04%↑

VEEV

226.15

-0.01%↓

A

105.7

-0.57%↓

WBA

11

+0.09%↑

CHE

551.68

-1.39%↓

MDT

84.06

+0.04%↑

VEEV

226.15

-0.01%↓

A

105.7

-0.57%↓

WBA

11

+0.09%↑

CHE

551.68

-1.39%↓

MDT

84.06

+0.04%↑

VEEV

226.15

-0.01%↓

A

105.7

-0.57%↓

WBA

11

+0.09%↑

CHE

551.68

-1.39%↓

Search

Regeneron Pharmaceuticals Inc

Abierto

SectorSanidad

594.49 0.07

Resumen

Variación precio

24h

Actual

Mínimo

583.66

Máximo

599.49

Métricas clave

By Trading Economics

Ingresos

-423M

918M

Ventas

69M

3.8B

P/B

Media del Sector

14.641

57.333

BPA

12.07

Rentabilidad por dividendo

0.63

Margen de beneficios

24.219

Empleados

15,106

EBITDA

-534M

1.1B

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 Meses

+47.02% upside

Dividendos

By Dow Jones

Rentabilidad por dividendo

Media del Sector

0.63%

2.63%

Próximas Ganancias

29 abr 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

-13B

62B

Apertura anterior

594.42

Cierre anterior

594.49

Puntuación técnica

By Trading Central

Confianza

Very Strong Bullish Evidence

Regeneron Pharmaceuticals Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

4 feb 2025, 12:13 UTC

Ganancias

Regeneron 4Q Revenue Up on Strong Sales of EYLEA HD

22 abr 2025, 10:51 UTC

Principales Noticias

Drug Companies Step Up 'Make in America' Plans to Counter Tariffs -- WSJ

28 feb 2025, 12:00 UTC

Principales Noticias

Drug Stocks Are the New Safe Bet in a Shaky Market -- Heard on the Street -- WSJ

4 feb 2025, 11:58 UTC

Ganancias

Regeneron 4Q Rev Up on Strong Sales of EYLEA HD

4 feb 2025, 11:37 UTC

Ganancias

Regeneron Pharma Sees 2025 Adjusted R&D $5B-$5.2B >REGN

4 feb 2025, 11:37 UTC

Ganancias

Regeneron Pharma Sees 2025 Gross Margin on Net Product Sales 87%-88% >REGN

4 feb 2025, 11:36 UTC

Ganancias

Regeneron Pharma Sees 2025 Capital Spending $850M-$975M >REGN

4 feb 2025, 11:35 UTC

Ganancias

Regeneron Pharma Declares Initial Quarterly Dividend of 88c >REGN

4 feb 2025, 11:35 UTC

Ganancias

Regeneron Pharma 4Q Adj EPS $12.07 >REGN

4 feb 2025, 11:34 UTC

Ganancias

Regeneron Pharma 4Q U.S. Net Sales for Eylea HD, Eylea Rose 2% to $1.5B >REGN

4 feb 2025, 11:34 UTC

Ganancias

Regeneron Pharma: 4Q Dupixent Global Net Sales Recorded by Sanofi Rose 15% to $3.7B >REGN

4 feb 2025, 11:32 UTC

Ganancias

Regeneron Pharma Board OKs Additional $3 Billion Share Repurchase >REGN

4 feb 2025, 11:31 UTC

Ganancias

Regeneron Pharma Initiates Quarterly Cash Dividend Program >REGN

31 ene 2025, 08:30 UTC

Adquisiciones, fusiones, absorciones

It's Bananas, but Stock Splits Can Pay Off. Here Are 5 Likely Contenders. -- Barrons.com

28 ene 2025, 10:30 UTC

Principales Noticias

Drug Companies Raise Prices on More Than 800 Drugs in January -- WSJ

31 oct 2024, 13:58 UTC

Ganancias

Regeneron Takes A Ghastly Turn As High-Dose Eylea Lags And Biosimilars Loom -- IBD

31 oct 2024, 10:52 UTC

Ganancias

Regeneron Earnings Top Views For Biotech Giant -- IBD

31 oct 2024, 10:34 UTC

Ganancias

Regeneron Pharma 3Q Adj EPS $12.46 >REGN

31 oct 2024, 10:33 UTC

Ganancias

Regeneron Pharma 3Q EPS Cut 43c by Acquired IPR&D Charge >REGN

31 oct 2024, 10:33 UTC

Ganancias

Regeneron Pharma 3Q U.S. Sales for Eylea HD, Eylea Rose 3% to $1.54B >REGN

31 oct 2024, 10:32 UTC

Ganancias

Regeneron Pharma: 3Q Dupixent Global Net Sales Recorded by Sanofi Rose 23% to $3.82B >REGN

31 oct 2024, 10:30 UTC

Ganancias

Regeneron Pharma 3Q Rev $3.72B >REGN

31 oct 2024, 10:30 UTC

Ganancias

Regeneron Pharma 3Q EPS $11.54 >REGN

31 oct 2024, 10:30 UTC

Ganancias

Regeneron Pharma 3Q Net $1.34B >REGN

25 oct 2024, 20:25 UTC

Ganancias

Sanofi Eyes Breakout After Pharma Titan Rides Vaccine Sales To Quarterly Beat -- IBD

1 ago 2024, 11:50 UTC

Ganancias

Regeneron Stock Climbs After Strong Second-Quarter Performance -- IBD

1 ago 2024, 10:37 UTC

Ganancias

Regeneron Pharma 2Q Adj EPS $11.56 >REGN

1 ago 2024, 10:30 UTC

Ganancias

Regeneron Pharma 2Q EPS $12.41 >REGN

1 ago 2024, 10:30 UTC

Ganancias

Regeneron Pharma 2Q Net $1.43B >REGN

1 ago 2024, 10:30 UTC

Ganancias

Regeneron Pharma 2Q Rev $3.55B >REGN

Comparación entre iguales

Cambio de precio

Regeneron Pharmaceuticals Inc previsión

Precio Objetivo

By TipRanks

47.02% repunte

Estimación a 12 Meses

Media 881.75 USD  47.02%

Máximo 1,120 USD

Mínimo 547 USD

De acuerdo con 21 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Regeneron Pharmaceuticals Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

21 ratings

17

Comprar

3

Mantener

1

Vender

Puntuación técnica

By Trading Central

554.18 / 603.77Soporte y Resistencia

Corto Plazo

Very Strong Bullish Evidence

Medio plazo

Weak Bullish Evidence

Largo Plazo

Bearish Evidence

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types; and with Sonoma Biotherapeutics, Inc. to discover, develop, and commercialize engineered regulatory T cell therapies. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.